Hypomethylation of CLDN4 Gene Promoter Is Associated with Malignant Phenotype in Urinary Bladder Cancer
Authors:
- Fumisato MaesakaFMFumisato Maesaka
- Masaomi KuwadaMKMasaomi Kuwada
- Shohei HoriiSHShohei Horii
- Shingo KishiSKShingo Kishi
- Rina Fujiwara-TaniRFRina Fujiwara-Tani
- Shiori MoriSMShiori Mori
- Kiyomu FujiiKFKiyomu Fujii
- Takuya MoriTMTakuya Mori
- Hitoshi OhmoriHOHitoshi Ohmori
- Takuya OwariTOTakuya Owari
- Makito MiyakeMakito Miyake
- Yasushi NakaiYNYasushi Nakai
Open Access
- 10 June 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6516
Abstract
The tight junction (TJ) protein claudin-4 (CLDN4) is overexpressed in bladder urothelial carcinoma (BUC) and correlates with cancer progression. However, the mechanism of CLDN4 upregulation and promotion of malignant phenotype is not clear. Here, we analyzed 157 cases of BUC and investigated the hypomethylation of CpG island in the CLDN4 promoter DNA and its correlation with cancer progression. In hypomethylated cases, CLDN4 expression, cell proliferation, stemness, and epithelial-mesenchymal transition were increased. Treatment of three human BUC cell lines with the demethylating agent aza-2′-deoxycytidine (AZA) led to excessive CLDN4 expression, and, specifically, to an increase in CLDN4 monomer that is not integrated into the TJ. The TJ-unintegrated CLDN4 was found to bind integrin β1 and increase stemness, drug resistance, and metastatic ability of the cells as well as show an anti-apoptosis effect likely via FAK phosphorylation, which reduces upon knockdown of CLDN4. Thus, CLDN4 is overexpressed in BUC by an epigenetic mechanism and the high expression enhances the malignant phenotype of BUC via increased levels of TJ-unintegrated CLDN4. CLDN4 promoter DNA methylation is expected to be a novel indicator of BUC malignant phenotype and a new therapeutic target.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (19K16564, 20K21659, 20K18007, 21K10143)
This publication has 44 references indexed in Scilit:
- Emerging Roles of Claudins in Human CancerInternational Journal of Molecular Sciences, 2013
- Methylation of the Claudin 1 Promoter Is Associated with Loss of Expression in Estrogen Receptor Positive Breast CancerPLOS ONE, 2013
- The Claudin family and its role in cancer and metastasisFrontiers in Bioscience-Landmark, 2011
- Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modificationsCarcinogenesis, 2010
- CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liverGut, 2009
- Prevention of murine experimental corneal trauma by epigenetic events regulating claudin 6 and claudin 9Japanese Journal of Ophthalmology, 2008
- DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinomaCarcinogenesis, 2007
- Colon Cancer Cell-Derived High Mobility Group 1/Amphoterin Induces Growth Inhibition and Apoptosis in MacrophagesThe American Journal of Pathology, 2005
- Expression, solubilization, and biochemical characterization of the tight junction transmembrane protein claudin‐4Protein Science, 2003
- Expression of receptors for advanced glycation end‐products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancerThe Journal of Pathology, 2001